Rockville, MD, USA, July 03, 2017 -- US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will address the global regulatory community on 10 September, delivering the opening keynote remarks at the 2017 Regulatory Convergence conference at National Harbor on the DC Waterfront. The Convergence is the largest annual meeting of healthcare product regulatory professionals and the signature annual event of the Regulatory Affairs Professionals Society (RAPS). It will take place 9–12 September at the Gaylord National Resort and Convention Center, National Harbor.
“Dr. Gottlieb has always been passionate and outspoken on public health policy, and we eagerly look forward to hearing directly from him on his vision for FDA and the overall direction of healthcare,” said RAPS Executive Director Paul Brooks. “RAPS is honored to have Dr. Gottlieb for one of his first large-scale public appearances as commissioner. I can’t think of a more fitting speaker to kick off our gathering of regulatory professionals from around the world.”
Gottlieb became the 23rd FDA commissioner in May. In his initial speech to agency staff, he called this “a time of great promise” for healthcare. Since taking over as head of FDA, he has identified addressing the national opioid addiction crisis, and increasing generic drug competition and speeding new generics to market as among his top priorities.
Gottlieb has an extensive resume, having worked in many prominent public health roles. He is a physician, medical policy expert and public health advocate who previously served as FDA’s deputy commissioner for medical and scientific affairs and before that, as a senior advisor to the commissioner. Prior to being sworn in as FDA commissioner, he was a resident fellow at the American Enterprise Institute and a clinical assistant professor at the New York University School of Medicine.
Members of the media who wish to cover all or part of RAPS’ Regulatory Convergence should contact Zachary Brousseau, senior manager, communications for RAPS at [email protected] or +1 301 770 2920, ext. 245.
About RAPS
|
||||||||
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with offices in Shanghai and Singapore, and chapters and affiliates worldwide. www.RAPS.org
###
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6c6d1da7-c467-46b7-b969-2e25ebc67464
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2af00ae2-b373-4beb-9afd-3c14d3b87fa6
Zachary Brousseau Regulatory Affairs Professionals Society (RAPS) 301 770 2920, ext. 245 [email protected]


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



